AMENDMENTS TO THE SPECIFICATION

IN THE SPECIFICATION:

Page 9

Please amend paragraph [0016], at item [10] as indicated below:

[0016] Specifically, the gist of the present invention relates to:

[1] a composition comprising a nucleic acid of which target is at least one region selected from the group consisting of a juxtamembrane region, a kinase region and an ATP-binding site region in human Flt3 and which can inhibit the function of Flt3,

[2] a composition comprising a nucleic acid of which target is at least one region selected from the group consisting of the following (a) to (c) and which can inhibit the function of Flt3:

(a) a region corresponding to a cDNA nucleotide sequence of a juxtamembrane region in human normal Flt3 set forth in SEQ ID NO: 27,

(b) a region corresponding to a cDNA nucleotide sequence of a kinase region in human normal Flt3 set forth in SEQ ID NO: 28, and

(c) a region corresponding to a cDNA nucleotide sequence of an ATP-binding site region in human normal Flt3 set forth in SEQ ID NO: 29,

[3] the composition according to the above-mentioned [1] or [2], wherein the composition comprises a nucleic acid having a length of 15 to 25 bases,

[4] the composition according to the above-mentioned [1] or [2], wherein the composition comprises an RNA sequence corresponding to at least one nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 4, 7, 32, 35 and 38,

[5] the composition according to any one of the above-mentioned [1] to [4], wherein the composition comprises a nucleic acid selected from the group consisting of:

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 2 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 3 are combined,

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 5 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 6 are combined,

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 8 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 9 are combined,

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 33 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 34 are combined,

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 36 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 37 are combined, and

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 39 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 40 are combined,

[6] a composition comprising a vector carrying a nucleic acid of which target is at least one region selected from the group consisting of a juxtamembrane region, a kinase region and an ATP-binding site region in human Flt3 and which can inhibit the function of Flt3,

[7] a composition comprising a vector carrying a nucleic acid of which target is a region selected from the group consisting of the following (a) to (c) and which can inhibit the function of Flt3 in mammalian cells:

(a) a region corresponding to a cDNA nucleotide sequence of a juxtamembrane region in human normal Flt3 set forth in SEQ ID NO: 27,

(b) a region corresponding to a cDNA nucleotide sequence of a kinase region in human normal Flt3 set forth in SEQ ID NO: 28, and

(c) a region corresponding to a cDNA nucleotide sequence of an ATP-binding site region in human normal Flt3 set forth in SEQ ID NO: 29,

[8] the composition according to the above-mentioned [6] or [7], wherein the nucleic acid has a nucleotide sequence of 15 to 25 bases of the target region,

[9] the composition according to the above-mentioned [6] or [7], wherein the composition comprises a vector carrying a nucleic acid corresponding to at least one nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 4, 7, 32, 35 and 38, and capable of expressing RNA corresponding to the nucleotide sequence,

[10] the composition according to any one of the above-mentioned ~~[6] to [9]~~ [6] to [7], wherein the composition comprises a vector carrying a nucleic acid selected from the group consisting of:

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 2 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 3 are combined,

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 5 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 6 are combined,

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 8 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 9 are combined,

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 33 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 34 are combined,

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 36 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 37 are combined, and

a nucleic acid wherein a nucleic acid having a nucleotide sequence of SEQ ID NO: 39 and a nucleic acid having a nucleotide sequence of SEQ ID NO: 40 are combined,

[11] the composition according to any one of the above-mentioned [6] to [10], wherein the composition comprises a vector having, as a promoter, an RNA polymerase III promoter or an RNA polymerase II promoter,

[12] the composition according to the above-mentioned [11], wherein the promoter is a promoter selected from the group consisting of a U6 promoter, an H1 promoter, a tRNA promoter and a CMV promoter,

[13] the composition according to any one of the above-mentioned [6] to [12], wherein the composition comprises, as a basic structure, a vector selected from an adenovirus vector, a lentivirus vector and a retrovirus vector,

[14] a method of inducing apoptosis, characterized by selectively inhibiting growth of FLT3 highly expressing cells and/or FLT3/ITD mutation-containing cells with the composition as defined in any one of the above-mentioned [1] to [13], thereby inducing apoptosis of the FLT3 highly expressing cells and/or FLT3/ITD mutation-containing cells,

[15] the method according to the above-mentioned [14], characterized by using an agent inhibiting kinase in addition to the composition simultaneously or in a manner using one after another, to selectively inhibit growth of FLT3 highly expressing cells and/or FLT3/ITD mutation-containing cells, thereby inducing apoptosis of the FLT3 highly expressing cells and/or FLT3/ITD mutation-containing cells, and

[16] a kit for carrying out the method as defined in the above-mentioned [14] or [15], wherein the kit comprises the composition as defined in any one of the above-mention [1] to [13].